Get the Stockscreener App
0.5773
0.93%
0.0053
Pre-market:
.58
0.0027
+0.47%
Vivos Therapeutics Inc stock is traded at $0.5773, with a volume of 396.19K.
It is up +0.93% in the last 24 hours and down -9.94% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$0.572
Open:
$0.561
24h Volume:
396.19K
Relative Volume:
0.30
Market Cap:
$8.02M
Revenue:
$19.57M
Net Income/Loss:
$-25.12M
P/E Ratio:
-0.2498
EPS:
-2.3114
Net Cash Flow:
$-19.71M
1W Performance:
-33.64%
1M Performance:
-9.94%
6M Performance:
-71.42%
1Y Performance:
-73.02%
1-Day Range:
$0.5151
$0.5799
1-Week Range:
$0.5151
$0.98
52-Week Range:
$0.5151
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.5773 | 8.02M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics Inc. (VVOS) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesLong-Term Guidance - The League of Women Voters of Texas
Vivos Therapeutics plans rights offering for shareholders - Investing.com
Vivos Therapeutics plans rights offering for shareholders By Investing.com - Investing.com Australia
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - The Manila Times
Vivos plans 9‑month tradable rights for shareholders to buy stock - Stock Titan
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - The Manila Times
VVOS: Capital-light, scalable sleep apnea treatment model targets rapid, profitable national expansion - TradingView
VVOS: Rapidly scaling sleep apnea treatment with high margins and unique FDA-cleared devices - TradingView
Vivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026 - Quiver Quantitative
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - The Manila Times
Vivos Therapeutics Announces $4.5 Million Debt-to-Equity Exchange Agreement to Support Nasdaq Listing and Strengthen Financial Position – Minichart - Minichart
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance - TipRanks
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Vivos Therapeutics, Inc. Reports Material Event - Stock Titan
Vivos Therapeutics agrees to debt-to-equity exchange with lender By Investing.com - Investing.com South Africa
6/5/2026 Market UpdateWinners: NOTV, STI, BGMSLosers: BIGGQ, NUWE, CYPHS&P 500: -2.6% - Trefis
Vivos Therapeutics Shares Surge After $4.5 Million Debt Conversion Fuels Nasdaq Optimism - TechStock²
Vivos Therapeutics (VVOS) Stock: Debt Exchange Plan Fuels Investor Optimism - parameter.io
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vivos Therapeutics agrees to debt-to-equity exchange with lender - Investing.com
Vivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial Position - Quiver Quantitative
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing - marketscreener.com
Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing - Moomoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - Yahoo Finance
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday - Benzinga
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - The Legal Advocate
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts By GuruFocus - Investing.com Canada
VVOS - Finviz
Vivos Therapeutics Balances Rapid Growth With Cash Strain - The Globe and Mail
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - The Globe and Mail
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com
Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Australia
BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView
Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo
Vivos Therapeutics Delays Quarterly Filing - TipRanks
Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan
Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan
Vivos Therapeutics | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB - Moomoo
TradingKey - TradingKey
VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks
3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan
VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):